In a nutshell This study aimed to investigate the benefits of monitoring early molecular response markers for chronic myeloid leukemia. This study concluded that monitoring BCR-ABL1 values at an early stage could help with assessing response and making decisions regarding timing of treatments. Some background Measuring molecular response markers...
Read More
In a nutshell This study aimed to investigate the effectiveness of nilotinib (Tasigna) as a consolidation therapy for chronic myeloid leukemia patients. This study concluded that nilotinib is safe and effective as a consolidation therapy in these patients. Some background Nilotinib is a targeted therapy used to treat chronic myeloid leukemia...
Read More
In a nutshell This study investigated the interactions between tyrosine kinase inhibitors and other drugs taken at the same time in patients with chronic myeloid leukemia. This study concluded that drug interactions were found in a significant number of patients, with mild side effects. Some background Imatinib (Gleevec) and similar drugs are the...
Read MoreIn a nutshell This study aimed to investigate the safety of venetoclax (Venclexta) in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax is safe in these patients as a long-term continuous therapy. Some background Venetoclax is a treatment used for patients with relapsed/refractory (RR)...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read More
In a nutshell This study aimed to investigate the effectiveness of venetoclax (Venclexta) and rituximab (Rituxan) treatment in patients with relapsed/refractory chronic lymphocytic leukemia. This study concluded that venetoclax-rituximab treatment was effective for these patients. Some background Chronic lymphocytic leukemia...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna) in chronic phase chronic myeloid leukemia patients with failed imatinib (Gleevec) treatment. This study concluded that dasatinib and nilotinib were safe and effective in this group of patients. Some background Chronic...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors. This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses. Some background...
Read More
In a nutshell This study examined outcomes in chronic myeloid leukemia (CML) patients with different types of a genetic abnormality known as BCR-ABL1. While patients with the BCR-ABL transcript e14a2 showed better response to treatment, long-term outcomes were similar between groups. Some background Certain genetic changes in CML can make it more...
Read More
In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...
Read More
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with idelalisib (Zydelig). Researchers reported good response rates and a low rate of side effects for venetoclax after idelalisib. Some background Targeted therapy is the standard treatment of CLL. This includes the...
Read More
In a nutshell This study examined outcomes after discontinuation of imatinib (Gleevac) in patients with chronic myeloid leukemia (CML). Researchers reported that some CML patients can safely discontinue imatinib after achieving a deep treatment response. Factors such as detectable residual leukemia cells after treatment affect the risk of losing...
Read More
